A New Hampshire overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
Just over three in ten adults in New Hampshire live with obesity: 31.1%, per the CDC's 2024 Behavioral Risk Factor Surveillance System estimate (crude prevalence, 95% CI 29.3%–32.9%, based on a sample of 6,331 NH adults) 1. That figure sits below the highest-prevalence states in the country, but it is still nearly one in three adults statewide — and the burden is not spread evenly.
In Manchester, New Hampshire's largest city, the CDC's PLACES program measured a higher rate: 35.0% crude prevalence (35.2% age-adjusted), using 2023 BRFSS data in its 2025 release 2. The state and city numbers come from two different CDC methodologies — a direct statewide survey versus a modeled small-area estimate — so they should not be read as a precise apples-to-apples comparison, but both point the same direction. Statewide population is 1,409,032 (Census Vintage 2024) 5.
Insurance coverage for GLP-1 medications in New Hampshire is changing on a specific, near-term date. Effective January 1, 2026, New Hampshire Medicaid will stop reimbursing GLP-1 drugs — Saxenda, Wegovy, Zepbound, and their generic equivalents — when they are prescribed solely for weight loss. That is confirmed in writing by two of the state's three Medicaid managed-care organizations: NH Healthy Families (a Centene plan), in an official notice dated October 14, 2025 3, and WellSense Health Plan, on its New Hampshire Medicaid prescriptions page 4. Both describe the change as a "New Hampshire Medicaid" policy rather than a plan-specific formulary decision, which points to a state-directed change rather than one insurer acting alone.
Coverage is not disappearing across the board: both plans confirm the same medications remain covered, subject to prior authorization, when prescribed for type 2 diabetes, major adverse cardiovascular events, severe obstructive sleep apnea, or MASH (metabolic dysfunction-associated steatohepatitis) 34.
We could not independently confirm whether the state's third Medicaid plan, AmeriHealth Caritas New Hampshire, is applying the identical rule, and New Hampshire's Department of Health and Human Services blocks automated access to its own bulletin pages — so as of this review (August 28, 2026), this is a two-of-three-plan confirmation, not a full state-agency statement, and worth a follow-up check before the cutoff takes effect.
Whatever New Hampshire Medicaid does or does not cover, Astra's own price does not move by state, or by city within it. Astra charges $68 per month for semaglutide and $118 per month for tirzepatide, both on 12-month plans billed annually — $816 and $1,416 per year, respectively — the same in Manchester as in every other city Astra serves. There is no New Hampshire-specific price and no New Hampshire discount.
For context, New Hampshire's median household income is $99,782 (Census ACS, 2024 1-year estimate) 6 — among the highest of any state — which shapes what a monthly GLP-1 cost means to a New Hampshire household, even though it has no bearing on what Astra actually charges.
Outside Manchester, Nashua, and the Seacoast, in-person access to obesity-medicine and endocrinology specialists thins out fast across New Hampshire — exactly the gap telehealth is built to close: a licensed clinician, a video visit, and a prescription that does not require a drive to one of the state's few urban centers.
New Hampshire Board of Medicine / Office of Professional Licensure and Certification. TODO — Telehealth-prescribing rules for New Hampshire not yet verified; confirm with oplc.nh.gov before this section goes live. No URL is linked here because none has been confirmed.
Astra is licensed to treat patients in all 50 states, including New Hampshire — Manchester and every other New Hampshire city or town alike. Patients in Manchester can see local pricing context and start care today on Astra's Manchester GLP-1 page.
Astra treats patients in New Hampshire through state-licensed physicians.
Manchester's page carries the city's PLACES obesity estimate and local pricing context.
Not after January 1, 2026. Two of New Hampshire's three Medicaid managed-care plans — NH Healthy Families (per an October 14, 2025 notice) and WellSense Health Plan — confirm that New Hampshire Medicaid will stop covering GLP-1 medications (Saxenda, Wegovy, Zepbound, and generics) prescribed solely for weight loss, effective January 1, 2026. The same drugs stay covered, with prior authorization, for type 2 diabetes, major adverse cardiovascular events, severe obstructive sleep apnea, or MASH. New Hampshire's third Medicaid plan, AmeriHealth Caritas, hadn't published a matching notice as of this review.
No. Astra charges $68/month for semaglutide and $118/month for tirzepatide on 12-month plans ($816 and $1,416 billed annually) — the same price in New Hampshire as everywhere else Astra operates. There's no state-specific pricing or discount.
Yes — Astra is licensed to prescribe in all 50 states, including New Hampshire. [TODO: confirm New Hampshire's specific telehealth-prescribing requirements with the New Hampshire Board of Medicine before this page publishes.]
Statewide, 31.1% of New Hampshire adults have obesity (CDC BRFSS, 2024). In Manchester, the state's largest city, the measured rate is higher — 35.0% (CDC PLACES, 2025 release, using 2023 BRFSS data). The two figures come from different CDC survey methods, so they're directional, not a precise comparison — but both point to obesity being a larger burden in Manchester than statewide.
Yes. Astra is licensed in all 50 states, and patients anywhere in New Hampshire — including Manchester — can start treatment online today.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.